title: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
abstract: OBJECTIVE
  T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature. In some studies, pro-T and mature subtypes have a poor prognosis. The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  
  
  METHODS
  Between 1993 and 2003, 81 adult patients from 22 Spanish hospitals were included in two PETHEMA protocols: ALL-96 for standard-risk patients, and ALL-93 for high- risk patients. The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  
  
  RESULTS
  Of the 64 evaluable patients the distribution of the immunological subtypes was: 3 pro-T, 17 pre-T, 22 thymic or cortical and 22 mature. Patients with mature T-ALL had higher frequency of central nervous system involvement and myeloid antigen expression than those of the remaining subgroups. Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  
  
  CONCLUSIONS
  Although patients with mature T-cell ALL had a slow rate of response to treatment and their survival tended to be shorter, in the present study there were no statistically significant differences in the prognosis of the different subtypes of T-cell ALL.
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
authors.forename: Blanca
authors.initials: B
authors.lastname: Xicoy
authors.forename: Josep M
authors.initials: JM
authors.lastname: Ribera
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Sanz
authors.forename: Eugenia
authors.initials: E
authors.lastname: Abella
authors.forename: Mar
authors.initials: M
authors.lastname: Tormo
authors.forename: Eloy
authors.initials: E
authors.lastname: del Potro
authors.forename: Javier
authors.initials: J
authors.lastname: Bueno
authors.forename: Carlos
authors.initials: C
authors.lastname: Grande
authors.forename: Javier
authors.initials: J
authors.lastname: Fernández-Calvo
authors.forename: Maribel
authors.initials: M
authors.lastname: Orts
authors.forename: Andrés
authors.initials: A
authors.lastname: Novo
authors.forename: Concepción
authors.initials: C
authors.lastname: Rivas
authors.forename: Jesús M
authors.initials: JM
authors.lastname: Hernández-Rivas
authors.forename: Evarist
authors.initials: E
authors.lastname: Feliu
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Ortega
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis